Company
Evive Biotech is a global biologics company focused on oncology and inflammatory disorders. Developing a portfolio of novel therapies to deliver life-saving treatments for patients worldwide, we are devoted to being the leading Asian biologics company in advancing truly novel biologic products from pre-clinical studies to U.S. BLA submission and commercial launch.
Mission
Revolutionary remedies for a healthy and happy world.
Vision
Developing innovative medicines for patients worldwide.
Values
Entrepreneurial
Value-driven
Integrity
Validation
Excellence
What’s Going On
Our innovative assets have recently achieved significant milestones, including the completion of F-627's global Phase III clinical trials, which met its primary and secondary endpoints, the BLA submission of F-627 to the US FDA, and the receipt of orphan drug designation from the US FDA for F-652. We are engaging with potential partners and the broader scientific community to share our successes and to ensure broad access to treatment options for patients.
Evive Biotech Announces Recent Appointments: VP of Biometrics and VP of Clinical Operations
- 9 September 2021
Evive Biotech Announces IND Approval by the NMPA for a Phase II Clinical Study of F-652 in Patients with ACLF
- 8 September 2021
Evive Biotech Announces the Appointment of Dr. Lichuan Liu as Senior VP, Global Head of Clinical and Translational Science
- 2 September 2021
Evive Biotech Announces the Appointment of Dr. Weihai He as Senior VP, Global Head of Business Development
- 1 September 2021
Evive Biotech and Sino Biopharm Subsidiary Announce Strategic Collaboration to Commercialize F-627 in China
- 30 August 2021
Evive Biotech Announces the Appointment of Dr. Liping Sun as Senior VP, Global Head of R&D
- 8 July 2021
